Send to

Choose Destination
Leuk Lymphoma. 2018 Oct;59(10):2305-2317. doi: 10.1080/10428194.2018.1427858. Epub 2018 Feb 2.

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.

Author information

a Raffles Cancer Center , Raffles Hospital , Singapore.
b Department of Hematology , Singapore General Hospital , Singapore.
c Gil Hospital, Gachon University , Incheon , South Korea.
d Beijing Chaoyang Hospital, Capital Medical University , Beijing , China.
e Higashi Nagoya National Hospital , National Hospital Organization , Nagoya , Japan.
f Department of Haematology , Changzheng Hospital, The Second Military Medical University , Shanghai , China.
g Department of Hematology , Japanese Red Cross Medical Center , Tokyo , Japan.
h Chiang Mai Medical School , Maung , Thailand.
i National Taiwan University Hospital , Taipei , Taiwan.
j Queen Mary Hospital, University of Hong Kong , Hong Kong , China.
k Samsung Medical Center , Sungkyunkwan University , Seoul , South Korea.
l Department of Medical Oncology , Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi , India.
m Department of Internal Medicine , Postgraduate Institute of Medical Education and Research , Chandigarh , India.
n Cancer Science Institute of Singapore , National University of Singapore , Singapore.
o Department of Haematology-Oncology , National University Cancer Institute of Singapore National University Health System , Singapore.
p Cedars-Sinai Comprehensive Cancer Center , Los Angeles , CA , USA.


Predicated on our improved understanding of the disease biology, we have seen remarkable advances in the management of multiple myeloma over the past few years. Recently approved drugs have radically transformed the treatment paradigm and improved survivals of myeloma patients. The progress has necessitated revision of the diagnostic criteria, risk-stratification and response definition. The huge disparities in economy, healthcare infrastructure and access to novel drugs among different Asian countries will hinder the delivery of optimum myeloma care to patients managed in resource-constrained environments. In the light of the tremendous recent changes and evolution in myeloma management, it is timely that the resource-stratified guidelines from the Asian Myeloma Network be revised to provide updated recommendations for Asia physicians practicing under various healthcare reimbursement systems. This review will highlight the most recent advances and our recommendations on how they could be integrated in both resource-abundant and resource-constrained facilities.


Myeloma; novel agents; resource-stratified

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center